Niagen Bioscience
NAGE
140 hedge funds and large institutions have $102M invested in Niagen Bioscience in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 60 reducing their positions, and 26 closing their positions.
1,318% more call options, than puts
Call options by funds: $695K | Put options by funds: $49K
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
2% less funds holding
Funds holding: 143 → 140 (-3)
5.67% less ownership
Funds ownership: 45.8% → 40.13% (-5.7%)
35% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 60
37% less capital invested
Capital invested by funds: $162M → $102M (-$60.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.32M |
| 2 |
BlackRock
New York
|
+$1.27M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$691K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$542K |
| 5 |
SW
SteelPeak Wealth
Woodland Hills,
California
|
+$516K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$4.9M |
| 2 |
Renaissance Technologies
New York
|
-$2.72M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.27M |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$2.03M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.89M |
NAGE Hedge Fund Activity: Q2 2026 in Review
140 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2026, worth a combined $102M — down 37% from $162M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of NAGE and 24 opened new positions — a net loss of 2 holders — while 60 trimmed existing stakes and 39 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $1.32M. The largest seller was Arrowstreet Capital, cutting an estimated $4.9M.
- 140 institutional investors held Niagen Bioscience (NAGE) as of Q2 2026, down from 143 in Q1 2026.
- Funds reported $102M of Niagen Bioscience stock for Q2 2026, down 37% quarter-over-quarter.
- 24 funds opened new Niagen Bioscience positions in Q2 2026 and 26 closed out, a net change of -2 holders.
- The largest Niagen Bioscience buyer in Q2 2026 was Jacobs Levy Equity Management, an estimated $1.32M added.
- The largest Niagen Bioscience seller in Q2 2026 was Arrowstreet Capital, an estimated $4.9M sold.
Based on aggregated 13F filings for Q2 2026.